Emerging drugs for endometriosis
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Endometriosis is a benign, common gynecological disorder affecting mostly women of reproductive age. It is associated with dysmenorrhea, pelvic pain, and subfertility. The current non-surgical medical treatment is not satisfactory and there is a pressing need for novel therapeutics with better efficacy, tolerability and safety profiles. OBJECTIVE: To investigate the development of new therapies for endometriosis. METHODS: The PubMed database has been extensively searched for all compounds tested preclinically and clinically. RESULTS/CONCLUSION: Besides the three main classes of drugs, i.e., GnRH agonists, progestins, and androgenic agents, there are several classes of compounds that have been tested preclinically and clinically. Surprisingly, a considerable proportion of officially registered Phase II/III clinical trials are listed as completed yet no information on their outcomes is available. Three completed and published Phase II trials found the tested compound disappointing. Another two Phase II clinical trials have been suspended. This apparent gap between the generally promising preclinical findings and the clinical trial outcomes reflects our current woefully inadequate understanding of the mechanisms underlying endometriosis-associated pain and subferitility and recurrence of endometriosis; questions the adequacy and value of animal models of endometriosis that are still in use; highlights the difficulty in developing new therapeutics for endometriosis; and calls for more research in the mechanisms underlying endometriosis-associated pain and subferitility and recurrence of endometriosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956 · cited 2×
“For the PPAR- γ /RXR heterodimers, the binding of the ligand of either receptor can activate the complex, yet binding of both ligands simultaneously is more potent [177,178] .”
BackgroundThe PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816 · cited 6×
“(PPAR-g ) agonists and retinoid X receptor (RXR) ligands PPAR- γ is activated by fatty acid derivatives, thiazolidinediones (TZDs), and by certain NSAIDs [162,163] .”
BackgroundInfluentialESHRE guideline for the diagnosis and treatment of endometriosis
Kennedy, S., Bergqvist, A., Chapron, C., D’Hooghe, T., Dunselman, G., Greb, R., Hummelshoj, L., Prentice, A., & Saridogan, E. (2005) · Human Reproduction · doi:10.1093/humrep/dei135 · Cited by 1,584 · cited 4×
“All hormonal treatments are equally effective in relieving pains [13] ; however, the relief appears to be relatively shortterm [14] .”
BackgroundInfluentialAn integrative genomics approach to infer causal associations between gene expression and disease
Schadt, E. E., Lamb, J., Yang, X., Zhu, J., Edwards, S., GuhaThakurta, D., Sieberts, S. K., Monks, S., Reitman, M., Zhang, C., et al. (2005) · Nature Genetics · doi:10.1038/ng1589 · Cited by 1,043 · cited 1×
“Though piecemeal approaches may be necessary to dissect individual components of the system, developing a novel drug with the desired efficacy, tolerability and safety requires a system-wide approach [290,291] .”
BackgroundLaparoscopic Surgery in Infertile Women with Minimal or Mild Endometriosis
Marcoux, S., Maheux, R., & Bérubé, S. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370401 · Cited by 948
Nuclear factor-?B: its role in health and disease
Kumar, A., Takada, Y., Boriek, A., & Aggarwal, B. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0555-y · Cited by 933
Kao, L. C., Germeyer, A., Tulac, S., Lobo, S., Yang, J. P., Taylor, R. N., Osteen, K., Lessey, B. A., & Giudice, L. C. (2003) · Endocrinology · doi:10.1210/en.2003-0043 · Cited by 696 · cited 2×
“8 HDACIs Numerous studies have shown that many genes in endometriotic lesions are dysregulated [87,234,236] .”
BackgroundAromatase expression in endometriosis.
Noble, L. S., Simpson, E. R., Johns, A., & Bulun, S. E. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550748 · Cited by 566 · cited 2×
“For GnRH-a treatment, two sources of extraovarian estrogen production may render the treatment ineffective [20] : increased local production of estrogen within the ectopic implants due to aberrant expression of aromatase and 17 β HSD2 [21,22] , and estradiol produced in peripheral tissues.”
BackgroundVercellini, P., Fedele, L., Aimi, G., Pietropaolo, G., Consonni, D., & Crosignani, P. G. (2007) · Human Reproduction · doi:10.1093/humrep/del339 · Cited by 547 · cited 1×
“In addition, the association between endometriosis stage and severity of pelvic symptoms is marginal and inconsistent [285,286] .”
BackgroundBulun, S. E., Lin, Z., Imir, G., Amin, S., Demura, M., Yilmaz, B., Martin, R., Utsunomiya, H., Thung, S., Gurates, B., et al. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.3.6 · Cited by 531 · cited 4×
“In addition, they have many undesirable, and sometimes severe, side effects [15-17] .”
BackgroundInfluential
Cited by
Recurrence of endometriosis and its control
Guo, S.-W. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp007 · Cited by 719
Self-citationContemporary genetic technologies and female reproduction
The Evian Annual Reproduction (EVAR) Workshop Group 2010, Fauser, B. C. J. M., Diedrich, K., Bouchard, P., Dominguez, F., Matzuk, M., Franks, S., Hamamah, S., Simon, C., Devroey, P., et al. (2011) · Human Reproduction Update · doi:10.1093/humupd/dmr033 · Cited by 349
Guo, S.-W. (2009) · Molecular Human Reproduction · doi:10.1093/molehr/gap064 · Cited by 328
“Since drugs for treatment of endometriosis tacitly demand better side-effect profiles (Guo, 2008), side effects would be a legitimate concern.”
BackgroundInfluentialSelf-citation“Waiting for Godot”: a commonsense approach to the medical treatment of endometriosis
Vercellini, P., Crosignani, P., Somigliana, E., Vigano, P., Frattaruolo, M. P., & Fedele, L. (2011) · Human Reproduction · doi:10.1093/humrep/deq302 · Cited by 180
“…on the topic (D’Hooghe, 2003; Nothnick and D’Hooghe, 2003; Fedele and Berlanda, 2004; Olive et al., 2004; Attar and Bulun, 2006; Chlouber et al., 2006; Crosignani et al., 2006a; Mihalyi et al., 2006; Hompes and Mijatovic, 2007; Fedele et al., 2008; Guo, 2008; Panay 2008; Ferrero et al., 2010a).”
BackgroundNew treatment strategies and emerging drugs in endometriosis
Streuli, I., de Ziegler, D., Borghese, B., Santulli, P., Batteux, F., & Chapron, C. (2012) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2012.668885 · Cited by 27
Metadata
- Authors
- Guo, S.-W.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2008-11-20
- Volume
- 13
- Issue
- 4
- Pages
- 547-571
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2163398199
- Cited by
- 24
- References
- 56
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Emerging drugs for endometriosis. https://app.cochat.ai/papers/10.1517/14728210802548360
- The paper
- Guo, S.-W. (2008). Emerging drugs for endometriosis. Expert Opinion on Emerging Drugs. https://doi.org/10.1517/14728210802548360
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.